Scientists hunt for allergy genes in massive screening study
NCT ID NCT00852943
First seen Jun 27, 2026 · Last updated Oct 14, 2026 · Updated 21 times
Summary
This study screened up to 1,000 people with severe allergic conditions—like anaphylaxis, eczema, and asthma—along with their relatives to find genetic causes. Researchers collected blood samples and medical history to link specific gene mutations to these diseases. No treatment was given; the goal was to build a knowledge library to improve future diagnosis and therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
834 people
The number who actually took part.
- Started
-
Nov 2010
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Disorders of allergic inflammation and mast cell homeostasis and activation.
- Ages
-
1 day to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Subjects, ages birth to 99 years old, known to have or suspected of having an inherited or acquired genetic disorder resulting in severe allergic inflammation and/or reactivity associated with alterations in mast cell and/or eosinophil homeostasis or activation, will be eligible for enrollment. Because of the intensive time and labor required for research laboratory testing, subjects will be enrolled only if in the opinion of the investigator (based on discussions with the patient s private physician) there is a high index of suspicion of a genetic basis for the observed allergic manifestation(s). * Blood relatives of enrolled subjects will be eligible for enrollment. * There will be no discrimination as to age, gender, race, or disability. * Subjects must have a health care provider outside of the NIH. * Subjects must agree to have their blood stored for future studies of the immune system and/or other medical conditions. EXCLUSION CRITERIA: \- Ongoing systemic immune modulation with agents such as biologics that target mast cells and eosinophils, immune modulating or cytotoxic chemotherapy, and/or malignancy may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process would interfere with evaluation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart inhaler sensor help kids breathe easier?
- Can a new cream calm eczema itch and rash?
- Umbilical cord stem cells tested as lung disease therapy
- Can a daily skin cream keep childhood eczema Flare-Ups at bay?
- Everyday use of eczema drug upadacitinib under the microscope
- Can COVID-19 vaccines build strong immunity in people with weakened immune systems?